• Neurocrine Biosciences average debt/equity ratio for 2023 was 0.03, a 70% decline from 2022.
• Neurocrine Biosciences average debt/equity ratio for 2022 was 0.1, a 60% decline from 2021.
• Neurocrine Biosciences average debt/equity ratio for 2021 was 0.25, a 13.64% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.